IN2014DN07196A - - Google Patents

Info

Publication number
IN2014DN07196A
IN2014DN07196A IN7196DEN2014A IN2014DN07196A IN 2014DN07196 A IN2014DN07196 A IN 2014DN07196A IN 7196DEN2014 A IN7196DEN2014 A IN 7196DEN2014A IN 2014DN07196 A IN2014DN07196 A IN 2014DN07196A
Authority
IN
India
Prior art keywords
parkinson
disease
patients
patient
systems
Prior art date
Application number
Other languages
English (en)
Inventor
Arthur L Hewitt
William Schwieterman
Cameron Szakacs
Gerry Rowse
Christopher Cioffi
Michael J Roberts
Original Assignee
Lundbeck Na Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck Na Ltd filed Critical Lundbeck Na Ltd
Publication of IN2014DN07196A publication Critical patent/IN2014DN07196A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IN7196DEN2014 2012-01-31 2013-01-30 IN2014DN07196A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261592755P 2012-01-31 2012-01-31
PCT/US2013/023828 WO2013116325A1 (fr) 2012-01-31 2013-01-30 Amélioration de la stabilité posturale par administration de droxidopa

Publications (1)

Publication Number Publication Date
IN2014DN07196A true IN2014DN07196A (fr) 2015-04-24

Family

ID=47714573

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7196DEN2014 IN2014DN07196A (fr) 2012-01-31 2013-01-30

Country Status (14)

Country Link
US (1) US20130197090A1 (fr)
EP (1) EP2809315A1 (fr)
JP (1) JP2015505563A (fr)
KR (1) KR20140131335A (fr)
CN (1) CN104220059A (fr)
AU (1) AU2013215282A1 (fr)
BR (1) BR112014018851A2 (fr)
CA (1) CA2863585A1 (fr)
CO (1) CO7141467A2 (fr)
HK (1) HK1200331A1 (fr)
IL (1) IL233855A0 (fr)
IN (1) IN2014DN07196A (fr)
SG (1) SG11201404496PA (fr)
WO (1) WO2013116325A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5880913B2 (ja) * 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
CN104434868A (zh) * 2013-09-18 2015-03-25 重庆圣华曦药业股份有限公司 一种稳定且利于在消化道溶出的屈昔多巴口服剂型
SG11201901477PA (en) 2016-08-30 2019-03-28 Theravance Biopharma R&D Ip Llc Compound for use in the treatment of neurogenic orthostatic hypotension
US10902955B1 (en) * 2020-05-01 2021-01-26 Georgetown University Detecting COVID-19 using surrogates
WO2021247963A1 (fr) * 2020-06-05 2021-12-09 Senda Biosciences, Inc. (s)-alpha-fluorométhyltyrosine en tant qu'inhibiteurs de décarboxylase pour une utilisation dans le traitement de l'hypotension

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920728A (en) 1973-08-22 1975-11-18 Hoffmann La Roche Separation and resolution of isomeric forms of 3-(3,4-dihydroxy-phenyl)-serine
JPS5629551A (en) 1979-08-20 1981-03-24 Sumitomo Chem Co Ltd Preparation of optically active threo-3- 3,4- dihydroxyphenyl serine
US4480109A (en) 1982-01-14 1984-10-30 Sumitomo Chemical Company, Limited Process for producing threo-3-(3,4-dihydroxyphenyl)serine
CA1223602A (fr) 1983-05-25 1987-06-30 Naohito Ohashi Preparation de 3-(3,4-dihydroxyphenyl)-serine
JPS6098995A (ja) 1983-11-04 1985-06-01 Microbial Chem Res Found 光学活性３−（３，４−ジヒドロキシフエニル）セリン，およびその誘導体の製造法
US5288898A (en) 1985-09-30 1994-02-22 Zaidan Hojim Biseibutsu Kagaku Kenkyu Kai N-methylphenylserine alkyl ester derivatives and uses thereof
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
DE19619510A1 (de) 1995-05-18 1996-11-21 Sumitomo Chemical Co Verfahren zur Herstellung von Threo-3-(3,4-dihydroxyphenyl)serin
GB9510481D0 (en) 1995-05-24 1995-07-19 Orion Yhtymae Oy New catechol derivatives
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
US7897639B2 (en) 2003-10-21 2011-03-01 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
US8980316B2 (en) * 2005-05-18 2015-03-17 Sumitomo Dainippon Pharma Co., Ltd. Stable tablet containing droxidopa
PT1948155E (pt) 2006-06-28 2012-06-15 Chelsea Therapeutics Inc Composições farmacêuticas contendo droxidopa
ES2480966T3 (es) 2007-03-09 2014-07-29 Chelsea Therapeutics, Inc. Droxidopa y composición farmacéutica de la misma para el tratamiento de la fibromialgia

Also Published As

Publication number Publication date
CA2863585A1 (fr) 2013-08-08
HK1200331A1 (en) 2015-08-07
BR112014018851A2 (pt) 2017-07-04
CO7141467A2 (es) 2014-12-12
SG11201404496PA (en) 2014-12-30
US20130197090A1 (en) 2013-08-01
EP2809315A1 (fr) 2014-12-10
CN104220059A (zh) 2014-12-17
KR20140131335A (ko) 2014-11-12
IL233855A0 (en) 2014-09-30
JP2015505563A (ja) 2015-02-23
AU2013215282A1 (en) 2014-08-28
WO2013116325A1 (fr) 2013-08-08

Similar Documents

Publication Publication Date Title
AU2024202233A1 (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
JOP20180103B1 (ar) التركيب الصيدلاني للكاربيتوسين
IN2014DN07196A (fr)
MX337454B (es) Composicion acuosa que contiene bromhexina.
PH12015500850A1 (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
IN2014KN02601A (fr)
MX2013001677A (es) Formulaciones estables de linaclotida.
IN2014DN10386A (fr)
MX351584B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
UA111343C2 (uk) Фармацевтична композиція, що містить мометазону фуроат та азеластину гідрохлорид, для назального введення
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
BR112015008297A2 (pt) antagonistas de mglu2/3 para o tratamento de distúrbios autistas
IN2014CN02364A (fr)
BR112013017314A2 (pt) composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos
TN2013000386A1 (en) Suspension type topical formulations comprising cyclic depsipeptide
MX342859B (es) Polisacarido de las semillas de tamarindo para usarse en el tratamiento de enfermedades inflamatorias.
MX361369B (es) Modificaciones cristalinas estables de cloruro de dotap.
AU2018253542A1 (en) Reducing inter-patient variability of levodopa plasma concentrations
EA201500155A1 (ru) Фармацевтические композиции, содержащие ипидакрин, и их применение для лечения нарушений потенции и нарушений других форм половой активности
MX358072B (es) Composiciones tópicas que comprenden diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que involucran un aumento del dolor.
GB201111427D0 (en) Novel bisindolylmaleimides, pan-pkc inhibitors
TR201104738A2 (tr) N-Asetilsistein içeren farmasötik kombinasyon.